Secondhand Tobacco Smoke and Cardiovascular Disease
Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
This is a double-blind randomized placebo-controlled crossover clinical trial of efficacy and
safety of an FDA-approved angiotensin receptor blocker (losartan) to improve cardiopulmonary
outcomes in individuals with pre-Chronic Obstructive Pulmonary Disease (COPD) due to
prolonged exposure to secondhand tobacco smoke.
Phase:
Phase 4
Details
Lead Sponsor:
University of California, San Francisco
Collaborator:
Flight Attendant Medical Research Institute
Treatments:
Angiotensin II Angiotensin Receptor Antagonists Antihypertensive Agents Losartan